On Jan. 26, the FDA revoked its emergency use authorization for Evusheld, a monoclonal antibody authorized to treat COVID-19, after finding it’s ineffective against about 90 percent of circulating ...

The US Food and Drug Administration on Thursday halted the emergency use authorization of Evusheld because it does not appear to protect against COVID-19 from viral variants currently circulating in ...

Evusheld, the only COVID-19 preexposure prophylaxis treatment with emergency use authorization, may not be effective against subvariant XBB.1.5, which makes up nearly 3 in 10 cases, the FDA said Jan.

(The Hill) — Evusheld, the preventative monoclonal antibody treatment for COVID-19, has lost its emergency use authorization in the U.S. as it is most likely not effective against the strains of the ...